GlassScriptPhysician profile
Scott Jarrett Ramshur
NPI 1437231396
$1,288.64
in general payments reported to CMS, 2019-2025
20 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.70 · 2022: $132 · 2023: $378 · 2024: $317 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $134.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $110.68 | 2023-2024 | |
| Exact Sciences Corporation | $104.18 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $99.55 | 2025 | Inspire |
| Viiv Healthcare Company | $85.59 | 2022-2025 | Apretude |
| Glaxosmithkline, LLC. | $71.50 | 2022-2024 | Shingrix, Arexvy |
| Pfizer INC. | $71.44 | 2023-2025 | |
| Boston Scientific Corporation | $55.87 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $31.34 | 2023 | Venaseal |
| Dynavax Technologies Corporation | $30.93 | 2023 | Heplisav-B |
| Edwards Lifesciences Corporation | $29.29 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $28.76 | 2021-2025 | Lagevrio |
| Saluda Medical Americas, INC. | $23.83 | 2024 | Evoke |
| Sanofi Pasteur INC. | $18.49 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.18 | 2024 | Mounjaro |
| Impel Pharmaceuticals INC. | $17.81 | 2023 | Trudhesa |
| Esperion Therapeutics, INC. | $16.28 | 2021 | |
| Currax Pharmaceuticals LLC | $14.08 | 2025 | Contrave |
| Gilead Sciences, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ramshur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.